Welcome to Pharmaceutical Executive Daily, your quick briefing on the top news shaping the pharmaceutical and life sciences industry.
In today's Pharmaceutical Executive Daily, the FDA issues a second complete response letter for Replimune's RP1 in advanced melanoma, Regeneron and Telix Pharmaceuticals announce a radiopharmaceutical collaboration worth up to $2.1 billion, and Pharmaceutical Executive speaks with Matt Holms of Citeline on improving patient experience and real-world evidence integration in clinical trials.
The FDA has issued a second complete response letter for Replimune's biologics license application for RP1 in combination with nivolumab for adult patients with advanced melanoma who have progressed on an anti-PD-1 regimen. The CRL cites the agency's inability to confirm RP1's individual contribution to the combination's efficacy from the single-arm Ignyte trial, despite the drug holding breakthrough therapy designation and showing a 34% response rate with a median duration of response of nearly 25 months. Replimune CEO Sushil Patel issued a sharp public statement accusing the FDA of inconsistent communication and contradictory positions relative to prior meetings, and said the company has no choice but to eliminate jobs and substantially scale back its U.S.-based manufacturing operations.
Regeneron Pharmaceuticals and Telix Pharmaceuticals have entered into a strategic collaboration to jointly develop and commercialize next-generation radiopharmaceutical therapies, with Telix receiving $40 million upfront and eligible for up wards of $2.1 billion in development and commercial milestone payments across four initial programs, plus low double-digit royalties. The deal pairs Regeneron's antibody discovery platform with Telix's end-to-end radiopharmaceutical infrastructure covering radiochemistry, manufacturing, and global supply chain.
Finally, Pharmaceutical Executive speaks with Matt Holms, vice president of commercial, patient engagement, and recruitment at Citeline, on the persistent gaps between clinical trial design and real-world patient experience. Holms argues that overly complex protocols remain one of the biggest structural challenges in trial execution, narrowing eligibility, increasing dropout rates, and slowing enrollment, and that recruitment and retention are too often treated as downstream execution issues rather than strategic design priorities.
Thanks for listening to Pharmaceutical Executive Daily. For more updates and in-depth analysis, visit PharmExec.com.
